[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bacterial-meningitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bacterial-meningitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,82,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100595055","acute-treatment-and-long-term-assessment-of-adult-infectious-meningitis-100595055",false,"NCT07027475","Acute Treatment and Long-term Assessment of Adult Infectious Meningitis","Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Adults Meningitis","ATLAS-I","Inclusion Criteria:\n\n* Fever (axillary temperature ≥37.8°C) followed by two or more of the following symptoms: severe headache, vomiting, altered consciousness (confusion, drowsiness, or irritability), photophobia (increased sensitivity to light), presence of seizures OR\n* Fever accompanied by at least one meningeal irritation sign, such as neck stiffness, Kernig's sign, or Brudzinski's sign OR\n* Sudden onset of fever and appearance of petechial skin rash or hemorrhagic suffusions\n\nExclusion Criteria:\n\n\\- Refusal to provide consent for study participation","ALL","18 Years",{"count":20,"type":21},624,"ESTIMATED","6 Months","OBSERVATIONAL","Prospective, multicenter, observational clinical registry of adult patients with acute infectious meningitis across approximately 30 public and private hospitals in Brazil. The study will include adults, 18 years old and older, with suspected acute infectious meningitis. Data will be collected during hospitalization and post-discharge to evaluate clinical management, treatment and short and long-term outcomes. The study aims to generate real-world evidence on current practices and outcomes to support improvements in national care protocols.",[26,27,28,29],"Viral Meningitis","Bacterial Meningitis","Fungal Meningitis","Meningitis",[29,31,32,33,34,35],"Bacterial","Viral","Corticosteroids","Antibiotics","Fungal","RECRUITING","2026-05-04",{"date":39,"type":40},"2026-05-07","ACTUAL",{"date":42,"type":40},"2026-03-30",{"date":44,"type":21},"2027-02",{"name":46,"class":47},"Hospital Israelita Albert Einstein","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100631013","intracalvariosseous-plus-intravenous-antibiotics-for-moderate-to-severe-bacterial-meningitis-100631013","NCT07495150","Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis","Efficacy and Safety of Intracalvariosseous Combined With Intravenous Injection of Antibiotics in Moderate-to-Severe Bacterial Meningitis","FLAME","Inclusion Criteria:\n\n* 1\\. Age 18-75 years, gender not limited;\n* 2\\. Meeting the diagnostic criteria for moderate to severe bacterial meningitis:\n\n  1. Meeting the diagnostic criteria for bacterial meningitis, i.e., meeting at least item i:\n\n     i. Abnormal body temperature (\\>38℃ or \\\u003C36℃), turbid or purulent Cerebrospinal fluid (CSF) , CSF leukocytosis (\\>500×10⁶\u002FL), CSF glucose\u002Fserum glucose concentration \\\u003C0.4, CSF protein concentration \\>50mg\u002FdL, meeting the clinical diagnosis; ii. In addition to item i, positive microbial tests or cultures of specimen smears, drainage tube heads, implants, and CSF (excluding contamination and colonization), meeting the etiological diagnosis;\n  2. GCS score ≤12 points or a decrease of 2 points from the previous score;\n  3. At least one of the following conditions is present: altered consciousness, seizures, brain parenchymal involvement, severe manifestations such as mechanical ventilation or circulatory support.\n* 3\\. After 48-72 hours of antibiotic treatment, if the investigator determines that the patient's condition shows no significant improvement or continues to worsen, or if at least one of the following conditions is present:\n\n  1. Symptoms and signs related to intracranial infection show no trend of relief or worsen;\n  2. CSF white blood cell count shows no trend of decrease, or increases after decreasing;\n  3. CSF protein concentration shows no trend of decrease, or increases after decreasing;\n  4. CSF\u002Fserum glucose concentration shows no trend of increase, or decreases after increasing;\n  5. CSF bacterial culture remains positive or becomes positive again after initially being negative.\n* 4\\. Based on the patient's condition, treatment with polymyxin B, tigecycline, or vancomycin may be necessary.\n* 5\\. Obtain informed consent.\n\nExclusion Criteria:\n\n* 1\\. History of allergy to polymyxin B, tigecycline, or vancomycin;\n* 2\\. Received intrathecal or intraventricular antibiotic treatment before randomization;\n* 3\\. Patients with severe pulmonary infection\u002Facute respiratory distress syndrome (PaO₂\u002FFiO₂ \\\u003C 150 mmHg, FiO₂ ≥ 0.6, PEEP ≥ 5 cmH₂O) or whose primary cause of mechanical ventilation is not determined to be intracranial infection;\n* 4\\. Patients with a primary extracranial infection focus (e.g., lungs, abdomen, urinary tract, etc.) who, after adequate fluid resuscitation, require vasoactive drugs to maintain MAP ≥ 65 mmHg (e.g., norepinephrine ≥ 0.25 μg\u002Fkg\u002Fmin) and lactate \\> 2 mmol\u002FL, or whose primary cause of critical illness is not determined to be intracranial infection;\n* 5\\. Patients with contraindications to transcranial administration, such as severe skull fracture, poor visualization of the skull diploic, or planned decompressive craniectomy, which may affect transcranial administration.\n* 6\\. Clinical signs of brain herniation, such as unilateral or bilateral pupillary dilation and fixation; or loss of other brainstem reflexes determined by the investigator to be caused by meningitis or brain herniation; or other uncontrollable signs of unstable vital signs;\n* 7\\. Bleeding tendency deemed unfavorable for the procedure by the investigator: abnormal coagulation function (e.g., platelet count \\\u003C50×10⁹\u002FL; prothrombin time \\[PT\\]\\>3s), patients with a previous diagnosis of hemophilia or other coagulation disorders;\n* 8\\. Patients with severe hepatic or renal insufficiency (where severe hepatic insufficiency is defined as alanine aminotransferase (ALT) value ≥3 times the upper limit of normal (ULN) or aspartate aminotransferase (AST) value ≥3 times the ULN; severe renal insufficiency is defined as serum creatinine (CRE) ≥1.5 times the ULN or glomerular filtration rate (eGFR) \\\u003C40 mL\u002Fmin\u002F1.73m²;\n* 9\\. Within the past 3 months, the patient has experienced an acute ST-segment elevation myocardial infarction and\u002For decompensated heart failure (meeting New York Heart Association \\[NYHA\\] functional class III or IV).\n* 10\\. Patients with severe or extremely severe anemia (hemoglobin \\\u003C 60 g\u002FL) at the time of randomization;\n* 11\\. Patients with active hepatitis B infection (positive hepatitis B surface antigen and\u002For positive serum HBV DNA or serum HBV DNA \\> 2 × 10⁸ IU\u002Fml);\n* 12\\. Patients with positive hepatitis C virus antibody or a history of positive testing;\n* 13\\. Patients with positive HIV test or a history of positive testing;\n* 14\\. Pregnant, lactating, or potentially pregnant patients, or patients planning to become pregnant;\n* 15\\. Patients currently participating in other interventional trials or who have used other investigational drugs within one month or five drug half-lives;\n* 16\\. Patients deemed unsuitable for participation in this study by the investigator.","75 Years",{"count":59,"type":21},86,"INTERVENTIONAL",[62],"NA","Multiple preclinical and clinical studies, including the investigators' published work and the ongoing SOLUTION series, have consistently demonstrated that intracalvariosseous (ICO) injection can markedly increase drug exposure within the central nervous system with acceptable safety. This trial is designed to further evaluate the efficacy and safety of antibiotic delivery via the ICO route in the treatment of bacterial meningitis, particularly in patients with moderate-to-severe disease who have shown an inadequate response to standard therapy.",[65,27],"Blood-Brain Barrier",[65,67,68,69,70],"Bacterial meningitis","Prognosis","Intracalvariosseous","Antibiotic","NOT_YET_RECRUITING","2026-03-21",{"date":74,"type":40},"2026-03-27",{"date":76,"type":21},"2026-04-01",{"date":78,"type":21},"2027-07-01",{"name":80,"class":47},"yilong Wang",6,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":93,"conditions":94,"keywords":101,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":48},"100624514","augmented-renal-clearance-in-neurocritical-care-100624514","NCT07410624","Augmented Renal Clearance in Neurocritical Care","Augmented Renal Clearance in Neurocritical Care Population: A Prospective Multicenter Study","Neuro-ARC","Inclusion Criteria:\n\n1. Age 18-85 years\n2. Admitted to ICU at one of the participating sites\n3. Diagnosis: SAH, TBI, ICH, meningitis, SE or ischemic stroke\n4. Provision of informed consent\n5. Foley catheter in place at time of consent (to facilitate urine collection)\n\nExclusion Criteria:\n\n1. Incarceration\n2. Anticipated ICU length of stay is \\\u003C 72 hours (insufficient time for monitoring)","85 Years",{"count":92,"type":21},512,"Stroke, severe brain injury, uncontrolled seizures and brain infections are the most common life-threatening neurological illnesses in the world with an estimated combined annual hospital management cost of up to 44 billion dollars. Seizures and infections are common complications following acute neurological illnesses and contribute significantly to poor outcomes if not promptly treated with appropriately dosed anti-seizure medications and antibiotics, respectively. Limited research suggested that many of those patients present with a phenomenon called augmented renal clearance (ARC) or, in other words, enhanced kidney function. ARC may have a significant influence on how medications are removed from the body potentially resulting in insufficient doses and treatment failure. Therefore, patients with ARC require higher medication doses; however, ARC is largely undetected using kidney assessment methods currently used in practice. In addition, it is not clear how medications should be dosed in those with ARC. The majority of ARC research has not focused on patients with life-threatening neurological illnesses. Thus, clinicians are likely under-dosing vital medications in those patients, and completely unaware. There is an immediate need to address the gap in knowledge. Therefore, this research aims to characterize the phenomenon of ARC in patients with life-threatening neurological illnesses through identifying the frequency, duration, contributing factors and clinical impact of ARC. Adult patients admitted to the neurosciences intensive care unit for life-threatening neurological illnesses will be enrolled in the study. Urine and blood samples wil be collected from participants to determine the presence of ARC and identify its contributing factors. In addition, blood samples will be collected from participants treated with select antibiotics and anti-seizure medications to determine their concentration and propose dose adjustment in those with ARC. This research is expected to improve the care of patients with life-threatening neurological illnesses through efficient identification and monitoring of patients exhibiting ARC facilitating timely medication dosage optimization. Furthermore, recommendations of optimal doses of commonly used medications in patients with ARC would improve the likelihood of treatment success with potential to improve patients' health and wellbeing.",[95,96,27,97,98,99,100],"TBI (Traumatic Brain Injury)","Status Epilepticus","Augmented Renal Clearance (ARC)","Subarachnoid Hemorrhage, Aneurysmal","Ischemic Stroke","Intracerebral Hemorrhage",[102,103,104,105,106,107,108,109,110,111,112,113,114,115,116],"traumatic brain injury","seizures","status epilepticus","bacterial meningitis","brain infections","neuro-ICU","augmented renal clearance (ARC)","augmented kidney function","creatinine clearance","neurological injury","TBI","ARC","subarachnoid hemorrhage","ischemic stroke","antimicrobials","2026-02-15",{"date":119,"type":40},"2026-02-18",{"date":121,"type":40},"2021-10-01",{"date":123,"type":21},"2026-09-30",{"name":125,"class":47},"University of Alberta",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":136,"conditions":137,"keywords":147,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100317883","central-nervous-system-infections-in-denmark-100317883","NCT03418441","Central Nervous System Infections in Denmark","Danish Study Group of Infections of the Brain: A Nationwide Prospective Observational Cohort Study of All Central Nervous System Infections in Adults at Departments of Infectious Diseases in Denmark","DASGIB","Definitions of central nervous system infections:\n\nFor all cases with unproven aetiologies no alternative diagnosis than CNS infection is thought more likely after completed multidisciplinary diagnostic work-up.\n\nViral meningitis inclusion criteria\n\n\\- All patients have to have a clinical presentation consistent with non-bacterial meningitis (e.g. headache, neck stiffness, photo- or phonophobia, fever)\n\nand\n\nCerebrospinal fluid leukocytes\\>10 cells\u002Fml\n\nPatients with viral meningitis with undetermined pathogen have to have:\n\n* CSF leukocytes\\> 10\u002FmL and no other more probable diagnosis assessed by the local investigator.\n\nIn case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.\n\nBacterial meningitis inclusion criteria - All patients have to have a clinical presentation consistent with bacterial meningitis (e.g. headache, neck stiffness, fever, altered mental status)\n\nand\n\nProven bacterial aetiology (CSF or blood culture\u002FDNA based technology or antigen tests)\n\nPatients with bacterial meningitis in whom the bacteria cannot not be cultured or identified by DNA-based technologies have to have:\n\n\\- CSF leukocytes\\> 10\u002FmL and no other more probable diagnosis assessed by the local investigator.\n\nIn case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.\n\nEncephalitis inclusion criteria - All patients have to have a clinical presentation consistent with encephalitis (e.g. headache, fever, focal neurological deficit, altered mental status \\>24 hours) as defined by the International Encephalitis Consortium (Venkatesan A et al., Clin Infect Dis 2013; doi:10.1093\u002Fcid\u002Fcit458.).\n\nEncephalitis exclusion criteria\n\n\\- We exclude cases of proven or suspected autoimmune encephalitis.\n\nPrimary brain abscess inclusion criteria\n\n\\- All patient have a clinical presentation consistent with brain abscess (e.g. headache, focal neurological deficit, mass lesion on cranial imaging)\n\nand\n\n\\- Proven microbiological aetiology by culture\u002FDNA-based technology from pus from brain abscess or blood or CSF\n\nor\n\n\\- Aspiration of pus from the brain abscess\n\nor\n\n\\- Response to antimicrobial treatment\n\nor\n\n\\- Tumour ruled out\n\nor\n\n\\- Tumour thought less probable than abscess on MRI using diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences.\n\nLyme neuroborreliosis inclusion criteria\n\n\\- A clinical presentation consistent with neuroborreliosis (e.g. radiculopathy)\n\nand\n\n\\- CSF pleocytosis\\>10 leukocytes\u002FmL\n\nand\n\n\\- Positive intrathecal B.burgdorferi antibody production index.\n\nNeurosyphilis inclusion criteria - A clinical presentation consistent with neurosyphilis (e.g. 'encephalitis-like symptoms', dementia, ocular or otogenic syphilis)\n\nand either\n\n\\- Positive syphilis serology in serum combined with CSF leukocytes\\>10\u002FmL\n\nor\n\n\\- CSF syphilis antibodies.",{"count":135,"type":21},1900,"The Danish Study Group of Infections of the Brain is a collaboration between all departments of infectious diseases in Denmark. The investigators aim to monitor epidemiological trends in central nervous system (CNS) infections by a prospective registration of clinical characteristics and outcome of all adult (\\>17 years of age) patients with community-acquired CNS infections diagnosed and\u002For treated at departments of infectious diseases in Denmark since 1st of January 2015.",[138,27,26,139,140,141,142,143,144,145,146,29],"Central Nervous System Infections","Aseptic Meningitis","Encephalitis","Brain Abscess","Neuroborreliosis","Neurosyphilis","Lyme Disease","Tertiary Syphilis","Cerebral Abscess",[148,149,138,29,140,150,151,142,143,152],"Nationwide prospective observational cohort study","Epidemiology","Brain abscess","Lyme disease","Tertiary syphilis","2024-05-15",{"date":155,"type":40},"2024-05-16",{"date":157,"type":40},"2015-01-01",{"date":159,"type":21},"2030-01-01",{"name":161,"class":47},"Aalborg University Hospital",8]